Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Catumaxomab intraperitoneal immunotherapy plus systemic chemotherapy for peritoneal carcinomatosis from colorectal or gastric adenocarcinoma
ISRCTN53770195Phase 2Completed
- Sponsor
- University of Witten/Herdecke
- Start
- Oct 2011
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of catumaxomab in colorectal cancer (CRC) and gastric cancer (GC), sponsored by University of Witten/Herdecke. Primary endpoints: Incidence of clinically significant malignant ascites, Incidence of intestinal obstruction requiring intervention and 2 more. Started Oct 2011; status: completed.
02
Drugs
catumaxomab
03
Conditions
colorectal cancer (CRC)gastric cancer (GC)
Beyond the preview
Go deeper on ISRCTN53770195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN53770195.